Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna MRNA shares jumped more than 9% in early trading Friday, reaching a fresh 52-week high as the biotechnology company ...

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at ...

Learn more Moderna (MRNA) and other vaccine developers were up on Friday after The New York Times reported that the National Institutes of Health is part of a public-private partnership to accelerate ...

Moderna ( MRNA) rose roughly 5% and Eli Lilly ( LLY) added nearly 3% to rank among the day’s best-performing stocks in the ...

In the recent earnings report, Moderna reiterated its forecast for as much as 10% revenue growth in the current year thanks ...

Arbutus Biopharma is a Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Click for more on ABUS stock.

Moderna stock rallied by triple digits on Aug. 19 with positive news for its cancer vaccine. Is mRNA ready to return to the ...

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.